湖南方盛制药股份有限公司关于中药创新药养血祛风止痛颗粒纳入国家医保目录（2025年）的公告

Group 1: Core Views - Hunan Fangsheng Pharmaceutical Co., Ltd. announced that its innovative traditional Chinese medicine, Yangxue Qufeng Zhitong Granules, has been included in the National Medical Insurance Directory for 2025, which is expected to enhance market promotion and sales scale [1][3] - The product is based on a modified formula of a well-known traditional Chinese medicine and aims to supplement qi and nourish blood while alleviating pain [1][2] Group 2: Drug Sales Situation - Yangxue Qufeng Zhitong Granules, classified as a Category 1 innovative traditional Chinese medicine, was approved for listing on June 9, 2025, but has not yet officially commenced sales [2] Group 3: Impact on the Company - The inclusion of Yangxue Qufeng Zhitong Granules in the medical insurance directory is anticipated to positively impact the company's future operating performance and market share, although it will not have a significant short-term effect [3] - The company has a strategic goal to become a health industry group centered on innovative traditional Chinese medicine, with plans to increase investment in research and market cultivation [3]